VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

Core Insights - VolitionRx Limited has made its first sale of Nu.Q® Cancer assays to Hospices Civils de Lyon, a leading cancer center in Europe, marking a significant milestone in the commercialization of its cancer diagnostic technology [1][3]. Company Developments - The order from Hospices Civils de Lyon is intended to complete the internal certification process before the test is introduced into routine clinical practice for cancer management [2]. - The collaboration with the Lyon team has resulted in strong scientific and clinical evidence supporting the use of Nu.Q® in managing cancer patients, particularly in Non-Small Cell Lung Cancer [3]. Product Impact - Nu.Q® Cancer technology is designed to enhance clinical decision-making by providing valuable information on survival and progression-free survival, thus improving patient outcomes [3]. - The technology aims to empower clinicians with better monitoring capabilities throughout the patient journey, ultimately supporting patient-centered care [3]. Market Position - This sale represents a major step for Volition in the human cancer diagnostics market, aligning with the company's mission to save lives through earlier detection and improved treatment monitoring [3][4]. - Volition is focused on developing cost-effective blood tests for various diseases, including cancers, which could significantly enhance early detection and patient quality of life [4].